INJ Search

CLOSE


Int Neurourol J > Volume 24(3); 2020 > Article
Kim, Ahn, Ko, Lee, Ha, Kim, Park, and Cho: Seasonal Variation of Drug Prescription Rate for Overactive Bladder in Men Based on National Health Insurance Claims Data, 2012–2016

ABSTRACT

Purpose

Overactive bladder (OAB) symptoms might be affected by weather, but only a few clinical studies have investigated this issue. We investigated seasonal variations in OAB-drug prescription rate (DPR) in men using nationwide claims data in Korea.

Methods

A total of 2,824,140 men aged over 18 years were included from the Health Insurance Review and Assessment service – National Patient Sample data between 2012 and 2016. Depending on the monthly average temperature, the seasons were divided into 3 groups, namely, hot (June, July, August, and September), intermediate (April, May, October, and November), and cold (January, February, March, and December) seasons. OAB-DPR was estimated using the claims data, and differences in its rate were examined among the 3 seasonal groups.

Results

The overall OAB-DPR was 1.97% (55,574 of 2,824,140). The OAB-DPR were 0.38%, 0.63%, 0.92%, 1.74%, 4.18%, 7.55%, and 9.69% in the age groups of under 30, 30s, 40s, 50s, 60s, 70s, and over 80 years, respectively; thus, the prescription rate increased with age (P<0.001), with a steeper increase after 60 years of age. OAB-DPR was 1.02% in the hot season, 1.19% in the intermediate season, and 1.27% in the cold season, with significant differences among the 3 seasonal groups (P<0.001). These seasonal variations persisted in the subgroup analysis in each age decade (P<0.001).

Conclusions

OAB-DPR varied with seasons and was significantly higher in the cold season than in the hot season, suggesting that cold weather may affect development and aggravation of OAB symptoms in men.

INTRODUCTION

Overactive bladder (OAB) is a prevalent cause of lower urinary tract symptoms (LUTS) defined as a syndrome of bladder storage function and characterized by a cluster of symptoms including urinary urgency, frequency, and nocturia with or without urinary incontinence [1]. Symptoms of OAB may have a detrimental impact on patients’ quality of life (QoL) and could lead to emotional distress, depression, anxiety, and sleep disturbances [2]. Multiple urological and nonurological risk factors are associated with the development of OAB, such as age, obesity, cognitive disorders, metabolic syndrome, neurologic disorders, and benign prostatic hyperplasia (BPH) [3].
There is also a widely held perception that LUTS vary in severity with seasonal changes, and, in particular, that they worsen in cold weather. According to the 5-year BPH patient-based dataset (2008–2012) of National Health Insurance in Korea, seasonal variations of visiting hospital patients are seen between summer and winter [4]. Several studies have addressed the associations between seasonal variations and LUTS. Yoshimura et al. [5] revealed that winter is an independent risk factor for urinary frequency, urgency, and nocturia. Choi et al. [6] also reported that seasonal variations are meaningfully associated with LUTS, particularly storage symptoms. Kobayashi et al. [7] demonstrated a significant seasonal difference in nocturia only, which showed a higher score in winter; however, no seasonal difference was seen in uroflowmetric parameters. However, Cartwright et al. [8] reported no significant variation in the urinary symptom scores or uroflowmetric parameters with changes in season. Watanabe et al. [9] also reported no seasonal differences in the urinary symptom scores, although maximum flow rate (Qmax) could be influenced by seasonal changes. On the other hand, Tae et al. [10] demonstrated that female OAB symptoms might be worse during cold season than in other seasons. As seen in the aforementioned studies, seasonal variation might be related to storage symptoms, but such a relationship remains controversial. To obtain robust evidence on this issue, we investigated seasonal variations in OAB-drug prescription rate (DPR) in men using nationwide claims data.

MATERIALS AND METHODS

1. Data sources and Study Sample

In South Korea, the National Health Insurance is a universal health coverage system that covers approximately 100% of Korean residents. The claims data of Health Insurance Review Agency (HIRA) is collected when healthcare service providers submit a claim to HIRA for reimbursement for a service that they provided to patients. The HIRA claims data represent 46 million patients each year, accounting for 90% of the total population in Korea. However, given the complexity and large volume of the dataset, its use is typically restricted to researchers. To resolve these limitations and increase the efficiency of data use, the HIRA developed patient sample data that passed validity tests performed by 5 different institutions [11]. Here, we used the national patient sample (NPS) of the HIRA claims data (HIRA-NPS) comprising randomized patients who used the National Health System at least once a year. This dataset passed validity tests performed by 5 different institutions and included 1.4 million patients overall per year (3%) [11]. In this study, we used HIRA-NPS, 2012–2016, from which all men aged over 18 years were included.

2. Climate Data and Seasonal Groups

South Korea’s location is 38°N, 127° 30' E; it is within a temperate climate region. Climate data were extracted from the Korea Meteorological Administration, and mean monthly temperatures were calculated (Table 1). According to the monthly average temperature, the seasons were divided into 3 groups: hot (June, July, August, and September), intermediate (April, May, October, and November), and cold (January, February, March, and December) seasons.

3. Definition of OAB

All available OAB drugs in Korea such as fesoterodine, imidafenacin, mirabegron, oxybutynin, propiverine, solifenacin, tolterodine, and trospium were included (Supplementary Table 1). OAB-DPR was calculated as the number of patients who were prescribed OAB drug among all patients during a certain period. The overall prescription rate was calculated, followed by the prescription rate according to the age and seasonal group.

4. Statistical Analysis

The chi-square test was used to investigate the association between OAB-DPR and seasonal variation. Logistic regression was used to assess the effect of each season on OAB-DPR, and odds ratios (ORs) and 95% confidence intervals (CI) were calculated. P values of ≤0.05 were considered statistically significant. All statistical analyses were performed using IBM SPSS Statistics ver. 25.0 (IBM Co., Armonk, NY, USA).

RESULTS

Of the total 7,223,663 people, 5,885,483 (81.48%) were aged over 18 years. Among them, 2,824,158 (47.99%) were men, and their mean age was 45.8±16.4. A total of 55,574 men (1.97%) were prescribed OAB drug once between 2012 and 2016, and their mean age was 62.4±15.3 (Fig. 1). OAB-DPR by age group was 0.38% in those under 30 years, 0.63% in those in their 30s, 0.92% in those in their 40s, 1.74% in those in their 50s, 4.18% in those in their 60s, 7.55% in those in their 70s, and 9.69% in those over 80 years (Table 2). Thus, the prescription rate increased with age, with a steeper increase after 60 years of age (Fig. 2).
In the present study, the seasons were divided into 3 groups as hot, intermediate, and cold seasons. The average temperatures were 23.6°C±2.3°C in the hot season, 13.5°C±4.0°C in the intermediate season, and 2.1°C±3.2°C in the cold season. There were significant differences in OAB-DPR among the seasonal groups, with the prescription rate being 1.02% (reference) in the hot season, 1.19% (OR, 1.170; 95% CI, 1.152–1.189) in the intermediate season, and 1.27% (OR, 1.244; 95% CI, 1.225–1.264) in the cold season (P<0.001) (Table 3). These seasonal variations persisted in the subgroup analysis of age decades (P<0.001) (Table 3).

DISCUSSION

Seasons of the year exerts an influence on certain disease conditions, such as coronary heart disease, cerebrovascular disease, and respiratory disease [12-14]. Our study demonstrated that OAB-DPR also varies among seasons: Specifically, it was significantly higher in the cold season than in the hot season, suggesting that cold weather may develop and aggravate OAB symptoms in men. This seasonal variation was consistently observed in each age group. To the best of our knowledge, our study is the first report to investigate the relationship between seasonal variation and OAB-DPR using a nationwide dataset. The presumptive explanation of this observation is as follows: the first is the response of the muscles to the cold stress. Cold stress increases sympathetic activity, which stimulates smooth muscle contraction in the prostate, and induces detrusor overactivity, which decreases voiding interval and volume [15,16]. The second is the change in diuresis with temperature. Diuresis is reduced by insensible fluid loss from sweating at high temperatures [17]. On the contrary, cold stress not only provokes peripheral vasoconstriction, which inhibits vasopressin secretion and leads to diuresis [18], but also stimulates the secretion of plasma atrial natriuretic peptide, which enhances diuresis [19]. The third is seasonal variation in vitamin D levels. Increasing evidence suggests that vitamin D deficiency or insufficiency is associated with LUTS [20]. Vitamin D status was found to be an independent significant predictor of OAB, with an increase of OAB risk by 44 times in patients with severe vitamin D deficiency [21]. The incidence of vitamin D deficiency was significantly higher during the winter than the summer [22,23]. These results suggest that seasonal changes in vitamin D influence seasonal OAB development.
In previous studies, seasonal variation was more pronounced in storage symptoms than in voiding symptoms (Table 4) [5-7]. The Japanese Urological Association recommends conservative treatment in which men with LUTS avoid exposing their lower body to cold temperatures [24]. A large retrospective study by Choi et al. [6] demonstrated that symptom severity as measured using the International Prostate Symptom Score (IPSS) was worse in the cold season group than in the hot season group. Storage symptom scores were significantly worse in the cold, and the QoL score showed a significant difference between the cold and hot seasons. In uroflowmetric parameters, voided volume and postvoid residue exhibited a significant seasonal change, but there was no significant difference in Qmax. Kobayashi et al. [7] announced that nocturia had seasonal variation in patients with BPH; however, there were no seasonal variation in the other IPSS categories and uroflowmetric parameters. Yoshimura et al. [5] performed a large community-based questionnaire study in Japan including 3 towns (Tobetsu at higher latitude [43°N], Kumiyama at middle latitude [35°N], and Sashiki at lower latitude [26°N]) and reported that 3 storage symptoms (frequency, urgency, and nocturia) demonstrated significant differences between summer and winter; such a difference was observed in relatively low latitude areas (Kumiyama and Sashiki) but not in higher latitude areas (Tobetsu). Likewise, a prospective study performed in Edinburgh, United Kingdom, showed no seasonal variation in urinary symptoms and uroflowmetric parameters [8]. Edinburgh is located at a relatively high latitude (55°N). These findings suggested that climate can influence seasonal variations in LUTS. Watanabe et al. [9] also explored changes in IPSS and uroflowmetric parameters associated with seasonal changes in 31 men with LUTS and found no significant seasonal change in IPSS or QoL but reported that Qmax exhibited a significant seasonal change, unlikely to expectation, being higher in the winter than in the summer. The authors mentioned that indoor temperatures in the winter were higher than outdoor temperatures due to central heating, whereas indoor temperatures in the summer were lower due to air-conditioning. However, the number of subjects was too small to draw concrete results.
Shim et al. [4] conducted a cross-sectional survey to investigate the association between daily temperature and LUTS in men and found that it was not affected by average daily temperature but was affected by diurnal temperature variations. Goriunov and Davidov [25] reported that the frequency of acute urinary retention (AUR) was affected by day-to-day temperature fluctuations (≥5°C) or a change in the atmospheric pressure (≥9 hPa) and humidity (≥20%). They studied the effect of daily temperature variations on LUTS or AUR and found that daily temperature variations did not reflect seasonal variations in weather because seasonal changes include not only changes in temperature but also those in other climatic factors such as humidity and total sunshine. Keller at al. [26] demonstrated that AUR was negatively correlated with ambient temperature, relative humidity, and rainfall and significantly correlated with hours of sunshine and atmospheric pressure.
In a large cross-sectional, population-based study in Korea, questionnaire-based OAB prevalence was 2.9% [27], but most studies reported 10%–20% OAB prevalence [2,28,29]. Such discrepancy can be explained by the differences in OAB definition, survey questionnaires for OAB, survey methods, and characteristics of the study populations. In our study, OAB-DPR was 1.97%. The prescription rate may differ from those prevalence rates surveyed, because our study was based on OAB-DPR, not on the diagnosis of OAB. This might be a limitation of our study, but it suggests that a significant number of patients with OAB symptoms require medical help. This study also had other limitations. First, since HIRA-NPS is not longitudinal database, it was impossible to obtain prior history of OAB diagnosis or OAB drug medication. This study did not include detailed clinical data on other comorbidities that could affect OAB. Second, the present study was based on OAB-DPR, not on the diagnosis of OAB. Third, the study year might be an important variable, but there was no difference in seasonal variation for each year (data not shown). Fourth, we performed the analysis using only the monthly average temperature of the country instead of using the temperatures corresponding to actual locations of the patients’ residences, although the range of latitude is relatively small in Korea. Despite these limitations, our study demonstrated that seasonal variation affects OAB-DPR, suggesting that seasonal changes can affect development of OAB symptoms that require medication.
In conclusions, OAB-DPR was affected by seasons, being significantly higher in the cold season than in the hot season. This suggests that cold weather may affect development and aggravation of OAB symptoms in men. Therefore, it may be helpful to consider seasonal changes when managing patients with OAB symptoms.

SUPPLEMENTARY MATERIALS

Supplementary Table 1 can be found via https://doi.org/10.5213/inj.2040030.015.

NOTES

Research Ethics
The present study protocol was reviewed and approved by the Institutional Review Board (IRB) of Gangnam Severance Hospital (IRB No. 3-2019-0340). Informed consent was waived by the IRB.
Conflict of Interest
Mr. Jae Hwan Kim and Ms. So Jeong Park are researchers of the Hanmi Pharmaceutical Co. Ltd., Seoul, Korea, but they made no influence on this work in relation with the company or its products. Other authors have no potential conflicts of interest to disclose.
AUTHOR CONTRIBUTION STATEMENT
·Conceptualization: SKK
·Formal Analysis: JYB, HKP
·Investigation: JYB, HKP
·Methodology: JYB, HKP
·Project Administration: JYB
·Writing – Original Draft: SKK
·Writing – Review & Editing: SKK

REFERENCES

1. Trinh H, Irish V, Diaz M, Atiemo H. Outcomes of intradetrusor onabotulinum toxin A therapy in overactive bladder refractory to sacral neuromodulation. Int Neurourol J 2019;23:226-33. PMID: 31607102
crossref pmid pmc pdf
2. Stensland KD, Sluis B, Vance J, Schober JP, MacLachlan LS, Mourtzinos AP. Predictors of nerve stimulator success in patients with overactive bladder. Int Neurourol J 2018;22:206-11. PMID: 30286584
crossref pmid pmc pdf
3. Son YJ, Kwon BE. Overactive bladder is a distress symptom in heart failure. Int Neurourol J 2018;22:77-82. PMID: 29991228
crossref pmid pmc pdf
4. Shim SR, Kim JH, Won JH, Song ES, Song YS. Association between ambient temperature and lower urinary tract symptoms: a community-based survey. Int Braz J Urol 2016;42:521-30. PMID: 27286116
crossref pmid pmc pdf
5. Yoshimura K, Kamoto T, Tsukamoto T, Oshiro K, Kinukawa N, Ogawa O. Seasonal alterations in nocturia and other storage symptoms in three Japanese communities. Urology 2007;69:864-70. crossref
6. Choi HC, Kwon JK, Lee JY, Han JH, Jung HD, Cho KS. Seasonal variation of urinary symptoms in Korean men with lower urinary tract symptoms and benign prostatic hyperplasia. World J Mens Health 2015;33:81-7. PMID: 26331124
crossref pmid pmc
7. Kobayashi M, Nukui A, Kamai T. Seasonal changes in lower urinary tract symptoms in Japanese men with benign prostatic hyperplasia treated with alpha1-blockers. Int Neurourol J 2017;21:197-203. PMID: 28954461
crossref pmid pmc pdf
8. Cartwright R, Mariappan P, Turner KJ, Stewart LH, Rajan P. Is there seasonal variation in symptom severity, uroflowmetry and frequency-volume chart parameters in men with lower urinary tract symptoms? Scott Med J 2014;59:162-6. PMID: 25005760
crossref pmid
9. Watanabe T, Maruyama S, Maruyama Y, Kageyama S, Shinbo H, Otsuka A, et al. Seasonal changes in symptom score and uroflowmetry in patients with lower urinary tract symptoms. Scand J Urol Nephrol 2007;41:521-6. PMID: 17853015
crossref pmid
10. Tae BS, Park TY, Jeon BJ, Chung H, Lee YH, Park JY, et al. Seasonal variation of overactive bladder symptoms in female patients. Int Neurourol J 2019;23:334-40. PMID: 31694352
crossref pmid pmc pdf
11. Kim L, Kim JA, Kim S. A guide for the utilization of Health Insurance Review and Assessment Service National Patient Samples. Epidemiol Health 2014;36:e2014008. PMID: 25078381
crossref pmid pmc pdf
12. Spencer FA, Goldberg RJ, Becker RC, Gore JM. Seasonal distribution of acute myocardial infarction in the second National Registry of Myocardial Infarction. J Am Coll Cardiol 1998;31:1226-33. PMID: 9581712
crossref pmid
13. Inagawa T, Shibukawa M, Inokuchi F, Tokuda Y, Okada Y, Okada K. Primary intracerebral and aneurysmal subarachnoid hemorrhage in Izumo City, Japan. Part II: management and surgical outcome. J Neurosurg 2000;93:967-75. PMID: 11117869
crossref pmid
14. Nakaji S, Parodi S, Fontana V, Umeda T, Suzuki K, Sakamoto J, et al. Seasonal changes in mortality rates from main causes of death in Japan (1970--1999). Eur J Epidemiol 2004;19:905-13. PMID: 15575348
crossref pmid pdf
15. Roehrborn CG, Schwinn DA. Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol 2004;171:1029-35. PMID: 14767264
crossref pmid
16. LeBlanc J. Mechanisms of adaptation to cold. Int J Sports Med 1992;13 Suppl 1:S169-72. PMID: 1483764
crossref pmid pdf
17. Kohn D, Flatau E. Points: why does cold weather cause frequency of micturition in some elderly people? Br Med J 1980;281:875. crossref
18. Stocks JM, Taylor NA, Tipton MJ, Greenleaf JE. Human physiological responses to cold exposure. Aviat Space Environ Med 2004;75:444-57. PMID: 15152898
pmid
19. Hassi J, Rintamaki H, Ruskoaho H, Leppaluoto J, Vuolteenaho O. Plasma levels of endothelin-1 and atrial natriuretic peptide in men during a 2-hour stay in a cold room. Acta Physiol Scand 1991;142:481-5. crossref
20. Parker-Autry CY, Burgio KL, Richter HE. Vitamin D status: a review with implications for the pelvic floor. Int Urogynecol J 2012;23:1517-26. PMID: 22415704
crossref pmid pmc pdf
21. Abdul-Razzak KK, Alshogran OY, Altawalbeh SM, Al-Ghalayini IF, Al-Ghazo MA, Alazab RS, et al. Overactive bladder and associated psychological symptoms: a possible link to vitamin D and calcium. Neurourol Urodyn 2019;38:1160-7. PMID: 30869826
crossref pmid
22. Sim MY, Kim SH, Kim KM. Seasonal variations and correlations between vitamin D and total testosterone levels. Korean J Fam Med 2017;38:270-5. PMID: 29026487
crossref pmid pmc pdf
23. Eloi M, Horvath DV, Szejnfeld VL, Ortega JC, Rocha DA, Szejnfeld J, et al. Vitamin D deficiency and seasonal variation over the years in Sao Paulo, Brazil. Osteoporos Int 2016;27:3449-56. PMID: 27339172
crossref pmid pdf
24. Homma Y, Araki I, Igawa Y, Ozono S, Gotoh M, Yamanishi T, et al. Clinical guideline for male lower urinary tract symptoms. Int J Urol 2009;16:775-90. PMID: 19811547
crossref pmid
25. Goriunov VG, Davidov MI. [The effect of meteorological factors on the incidence of acute urinary retention]. Urol Nefrol (Mosk) 1996;(1):4-7 Russian.
26. Keller JJ, Lin CC, Chen CS, Chen YK, Lin HC. Monthly variation in acute urinary retention incidence among patients with benign prostatic enlargement in Taiwan. J Androl 2012;33:1239-44. crossref
27. Kim SY, Bang W, Choi HG. Analysis of the prevalence and associated factors of overactive bladder in adult Korean men. PLoS One 2017;12:e0175641. PMID: 28407021
crossref pmid pmc
28. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001;87:760-6. crossref
29. Lee YS, Lee KS, Jung JH, Han DH, Oh SJ, Seo JT, et al. Prevalence of overactive bladder, urinary incontinence, and lower urinary tract symptoms: results of Korean EPIC study. World J Urol 2011;29:185-90. PMID: 19898824
crossref pmid pdf

Fig. 1.
Case extraction diagram. HIRA, Health Insurance Review and Assessment Service; NPS, National Patient Sample; OAB, overactive bladder.
inj-2040030-015f1.jpg
Fig. 2.
Drug prescription rate for overactive bladder in men according to seasons in each age decade.
inj-2040030-015f2.jpg
Table 1.
Monthly average temperature in South Korea from 2012 to 2016
Year Temperature (°C)
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2012 -1.2 -0.8 5.7 12.6 18.3 22.1 25.5 26.4 20.2 14.3 6.6 -1.7
2012 -1.2 -0.8 5.7 12.6 18.3 22.1 25.5 26.4 20.2 14.3 6.6 -1.7
2013 -2.1 0.7 6.6 10.3 17.8 22.6 26.3 27.3 21.2 15.4 7.1 1.5
2014 0.5 2.5 7.7 13.4 18.4 21.9 25.1 23.8 20.9 14.8 8.8 -0.5
2015 0.5 2 6.7 12.7 18.6 21.7 24.4 25.2 20.5 15 10.1 3.5
2016 -0.9 1.7 7.2 13.8 18.6 22.3 25.4 26.7 21.6 15.8 7.8 3.1
Totala) -0.6 ± 1.0 1.2 ± 1.2 6.8 ± 0.7 12.6 ± 1.2 18.3 ± 0.3 22.1 ± 0.3 25.3 ± 0.6 25.9 ± 1.2 20.9 ± 0.5 15.6 ± 0.5 8.1 ± 1.3 1.2 ± 2.0

a) Values are presented as mean±standard deviation.

Table 2.
Drug prescription rate for OAB according to age decades
Age (yr) Total patients Patient with OAB (%) Chi-square value
<30 30s 40s 50s 60s 70s
< 30 542,804 2,043 (0.38)
30–39 529,636 3,332 (0.63) 339.9***
40–49 593,346 5,476 (0.92) 1,271.3*** 310.4***
50–59 563,157 9,782 (1.74) 4,837.4*** 2,825.5*** 1,470.8***
60–69 335,422 14,025 (4.18) 16,710.3*** 13,179.2*** 11,067.9*** 4,869.6***
70–79 199,064 15,036 (7.55) 33,355.8*** 28,231.9*** 25,987.7*** 15,795.5*** 2,762.7***
≥ 80 60,711 5,880 (9.69) 36,521.8*** 29,080.7*** 24,785.4*** 14,146.0*** 3,263.1*** 285.6***

OAB, overactive bladder.

*** P<0.001 by Pearson chi-square test.

Table 3.
Drug prescription rate for OAB according to the seasonal groups and age decades
Age Total patients Season Patients with OAB (%) Logistic regression analysis
Odd ratio 95% CI P-value
Total 2,824,141 Hot 28,849 (1.02) Reference < 0.001
Intermediate 33,698 (1.19) 1.170 1.152–1.189
Cold 35,802 (1.27) 1.244 1.225–1.264
< 30 542,804 Hot 754 (0.14) Reference < 0.001
Intermediate 883 (0.16) 1.171 1.063–1.291
Cold 975 (0.18) 1.294 1.176–1.423
30s 529,636 Hot 1,349 (0.25) Reference < 0.001
Intermediate 1,549 (0.29) 1.149 1.068–1.236
Cold 1,597 (0.30) 1.184 1.101–1.274
40s 593,346 Hot 2,258 (0.38) Reference < 0.001
Intermediate 2,820 (0.48) 1.250 1.183–1.321
Cold 2,944 (0.50) 1.305 1.236–1.379
50s 563,157 Hot 4,582 (0.81) Reference < 0.001
Intermediate 5,494 (0.98) 1.201 1.155–1.249
Cold 6,090 (1.08) 1.333 1.282–1.385
60s 335,422 Hot 7,628 (2.27) Reference < 0.001
Intermediate 8,859 (2.64) 1.166 1.130–1.202
Cold 9,588 (2.86) 1.265 1.227–1.304
70s 199,064 Hot 8,732 (4.39) Reference < 0.001
Intermediate 10,082 (5.06) 1.163 1.129–1.197
Cold 10,494 (5.27) 1.213 1.178–1.249
≥ 80 60,711 Hot 3,546 (5.84) Reference < 0.001
Intermediate 4,011 (6.61) 1.140 1.088–1.195
Cold 4,114 (6.78) 1.172 1.119–1.227

OAB, overactive bladder; CI, confidence interval.

Table 4.
Characteristics of previously published studies and the present study comparing urinary symptoms according to seasons
Study Study design Subjects (n) Age (yr) Measures Location Season (mo) Average temperature (°C) Seasonal variation of urinary symptoms Seasonal variation of uroflowmetric parameter Seasonal variation of QoL
Watanabe, 2007 [9] Prospective, hospital-based Male patients with BPH/LUTS (31) 74.5 ± 6.8 IPSS Hamamatsu, Japan (34° E, 137° N) Hot (Jun, Jul, Aug, Sep) >20 No Yes (Qmax) No
QoL score Comfortable (Apr, May, Oct, Nov) 10–20
Uroflowmetry Cold (Jan, Feb, May, Dec) <10
Yoshimura et al. 2007 [5] Prospective, community-based Residents aged 41–70 yr 56.7 ± 7.9 IPSS Tobetsu, Japan (141° E, 43° N) Summer (Jun, Jul, Aug) 20.4 No NA NA
-Male (1,066) ICIQSF Winter (Jan, Feb) 4.4
-Female (1,214) Kumiyama, Japan (136° E, 35° N) Summer (Jun, Jul, Aug) 27.5 Yes (frequency, urgency) NA NA
Winter (Jan, Feb) 4.7
Sashiki, Japan (128° E, 26° N) Summer (Jun, Jul, Aug) 27.3 Yes (frequency, urgency, nocturia) NA NA
Winter (Jan, Feb) 16.3
Cartwright et al. 2014 [8] Prospective, hospital-based Male patients with LUTS (296) 62.3 IPSS Edinburgh, UK (3° E, 55° N) Spring (Mar, Apr, May) 8.1±2.2a) No No No
QoL score Summer (Jun, Jul, Aug) 14.6±1.2a)
Uroflowmetry Autumn (Sep, Oct, Nov) 9.9±2.7a)
Winter (Jan, Feb, Dec) 4.1±1.0a)
Choi et al. 2015 [6] Retrospective, hospital-based Male patients with BPH/LUTS (1,185) 62.1 ± 9.9 IPSS South Korea (124-130° E, 33-39° N) Hot (Jun, Jul, Aug, Sep) 24.0±2.6 Yes (storage symptoms) Yes (voided vol., residual vol.) Yes
QoL score Intermediate (Apr, May, Oct, Nov) 12.8±4.3
Uroflowmetry Cold (Jan, Feb, May, Dec) 1.0 ±3.2
Kobayashi et al. 2017 [7] Prospective, hospital-based BPH patients with alpha blocker, over 50 years (146) 70.9 ± 7.6 IPSS Utsunomiya, Japan (139° E, 36° N) Summer (Jun, Jul, Aug) 24.2±2.0 Yes (nocturia) NA No
OABSS Winter (Jan, Feb, Dec) 3.9±1.5
QoL score
Present study, 2019 Retrospective, papulation-based Men over 18 years old (2,824,140) 45.8 ± 16.4 Drug prescription rate for OAB South Korea (124-130° E, 33-39° N) Hot (Jun, Jul, Aug, Sep) 23.6±2.3 Yes NA NA
Intermediate (Apr, May, Oct, Nov) 13.5±4.0
Cold (Jan, Feb, May, Dec) 2.1±3.2

BPH, benign prostate hyperplasia; ICIQS, International Consultation on Incontinence Questionnaire short form; IPSS, International Prostate Symptom Score; LUTS, lower urinary tract symptoms; NA, not available; OAB, overactive bladder; QoL, quality of life; Qmax, maximum flow rate; UK, United Kingdom.

a) These data were calculated by extracting values from the graph of the paper.

TOOLS
Share :
Facebook Twitter Linked In Google+
METRICS Graph View
  • 1 Web of Science
  • 1 Crossref
  • 1 Scopus
  • 4,032 View
  • 85 Download
We recommend


ARTICLE & ORGAN
Article Category

Browse all articles >

Organ

Browse all articles >

ISSUES
DISEASES & TOPICS
Diseases

Browse all articles >

Topics

Browse all articles >

AUTHOR
INFORMATION

Official Journal of Korean Continence Society & ESSIC (International Society for the Study of BPS) & Korean Society of Urological Research & The Korean Children’s Continence and Enuresis Society & The Korean Association of Urogenital Tract Infection and Inflammation & Korean Society of Geriatric Urological Care
Editorial Office
Department of Urology, Kangbuk Samsung Medical Center, Sungkyunkwan University School of Medicine,
29 Saemunan-ro, Jongno-gu, Seoul 03181, Korea
Tel: +82-2-2001-2237     Fax: +82-2-2001-2247    E-mail: choys1011@naver.com

Copyright © 2024 by Korean Continence Society.

Developed in M2PI

Close layer
prev next